Health Care

#GPnews: Hope that new blood test could boost prostate cancer survival

#GPnews: Hope that new blood test could boost prostate cancer survival”

By looking for cancer DNA in blood samples, researchers were able to identify men with defective BRCA genes who were likely to benefit from a class of drugs called PARP inhibitors.

The study also found that the blood test could pick up the first signs that the tumour is evolving to become resistant to treatment, potentially speeding up efforts to try new lines of attack. Precision medicine or personalized medicine concerns the customization of healthcare.

Lynparza - abandoned at one stage by AstraZeneca but revived by CEO Pascal Soriot when he took over in 2012 - became the first PARP drug to reach the market when it won US approval for ovarian cancer at the end of 2014. In relation to the new research, medical laboratory testing could select the appropriate therapy for an individual person based on a given person's individual genetic make-up and particular physical characteristics.

More than 40,000 men in the United Kingdom are diagnosed with prostate cancer every year, making it the most common male cancer. This type of cancer describes the development of cancer in the prostate (a gland in the male reproductive system).

The men were taking part in a phase 2 clinical trial where they were treated with olaparib (Lynparza), a targeted cancer drug called a PARP inhibitor.

A new 3-in-1 blood test could revolutionise the treatment of prostate cancer, say scientists, and help pave the way for personalised patient treatment. Hence the need for a test to determine which individual patients would benefit and which would not.

These patients survived and average of 17 months compared with 10 months for those whose cancer DNA levels remained high.

They found that the cells acquired genetic changes that cancelled out the DNA fix defects making them susceptible to the drug.

"Blood tests for cancer promise to be truly revolutionary".

Bono said the three-in-one test may be used in the future to help doctors choose treatment for prostate cancer patients, check if the treatment is working, and track the cancer in the longer term. They found that cancer cells had acquired new genetic changes that canceled out the original errors in DNA repair-particularly in the genes BRCA2 and PALB2-that had made the cancer susceptible to olaparib in the first place.

'We think it could be used to make clinical decisions about whether a Parp inhibitor is working within as little as four to eight weeks of starting therapy.

In the future, the researchers believe the test could be used both before and after treatment.

"This is another important example where liquid biopsies - a simple blood test as opposed to an invasive tissue biopsy - can be used to direct and improve the treatment of patients with cancer". "That is why Prostate Cancer UK is investing so heavily in this area, including supporting this research released today".



Like this

Latest


19 June 2017
US Open a success for pair of Wisconsin golfers
After a 10th-place finish at The PLAYERS Championship, Noren enjoyed a massive come-from-behind win at the BMW PGA Championship. His 13-foot putt for birdie at the par-5 seventh moved him to 3 under for the day and 4 under for the tournament.

19 June 2017
Everton to make €20 million move for Jorgensen
As well as his strong finishing, the forward can pick out a pass and also has strength on the ball. Everton have raced out of the blocks in terms of getting transfer targets tied down.

19 June 2017
Powerball winner sold at California retailer
This big score will come in handy for Alberee's family, after his was diagnosed with pulmonary fibrosis earlier this year. The last Powerball drawing to produce a jackpot victor was on April 1, said California Lottery spokesman Mike Bond.

19 June 2017
May meets London blaze victims amid rising anger
The 91-year-old monarch said it is "difficult to escape a very somber mood" on what is normally a day of celebration. London Fire Brigade said the service has been "overwhelmed" by the support it has received from all over the world.

19 June 2017
Grenfell Tower's fire safety standards were praised by council 11 months ago
Cundy added that it will take weeks or longer to recover and identify all the dead in the housing block that was devastated. They also demanded more information over the full extent of the death toll, which has risen to at least 30.

19 June 2017
Trump hung United States out to dry on Paris climate agreement
Yes, our diet is pivotal. "The BMW Group has a long-standing and unwavering commitment to reducing greenhouse gas emissions". More than 190 nations came together in the French capital to agree to voluntary pledges to cut greenhouse gas emissions.

19 June 2017
Florentino Perez to continue as Real Madrid President
Ronaldo has been linked with a return to Old Trafford as he is unhappy in the Spanish capital. But we're a great side too, and I'm sure we can stop him.

19 June 2017
The Capital Fund Management SA Takes Position in Silgan Holdings Inc. (SLGN)
In other news, VP B Frederik Prinzen sold 3,204 shares of the business's stock in a transaction dated Thursday, May 11th. Menta Capital LLC purchased a new stake in Silgan Holdings during the fourth quarter worth approximately $2,092,000.

19 June 2017
4 killed in attack by extremists at Mali resort
On 20 November 2015, the Radisson Hotel in Bamako was the target of a similar attack, killing 20 tourists and two assailants. That attack was claimed by Al-Qaeda's North African affiliate Al-Qaeda in the Islamic Maghreb (AQIM ).

19 June 2017
US shoots down Syrian Air Force fighter
Share with Us - We'd love to hear eyewitness accounts, the history behind an article, and smart, constructive criticism. A Pentagon spokesman says the US had not shot down a Syrian regime aircraft before Sunday's confrontation.



Recommended